Compliance Trainings, Online
2016-04-12
This seminar will discuss the practical strategies for drug development via 505(b)(2) regulatory pathway. Key strategic considerations will be discussed using real-life case studies. Also discussed will be role of interactions with the FDA, global clinical trials, market access, reimbursement issues and projected trends for the near future. Lastly, the 505(b)(2) pathway will be compared to that for biosimilars. Areas Covered in the Session : The 505(B)(2) regulation and guidance from the FDA Strategic considerations before embarking on a 505(b)(2) development project Intellectual property issues with such products Key development steps for such products FDA’s review process and ongoing consultation Challenges to developing 505(b)(2) product and possible solutions Examples of successful strategies for developing such products Searching for a 505(b)(2) project, future trends 505(b)(2) and biosimilars Speaker's PASS-IT Recommendations Who Will Benefit: CEOs VPs Compliance Officers Attorneys Regulatory Affairs Clinical Affairs Quality Assurance Research & Development Project Managers Consultants Contractors/Subcontractors
|